Sprache: Englisch
Verlag: Nova Science Publishers, Incorporated, 2009
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 57,24
Anzahl: 1 verfügbar
In den WarenkorbZustand: New. pp. viii + 291.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2010
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: PBShop.store US, Wood Dale, IL, USA
HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2010
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: PBShop.store UK, Fairford, GLOS, Vereinigtes Königreich
EUR 82,88
Anzahl: 1 verfügbar
In den WarenkorbHRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2009
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. Num Pages: 291 pages, tables. BIC Classification: MBP. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 264 x 186 x 25. Weight in Grams: 830. . 2009. 1st Edition. Hardcover. . . . . Books ship from the US and Ireland.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 117,67
Anzahl: 1 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 1st edition. 291 pages. 10.00x7.00x0.75 inches. In Stock.
Sprache: Englisch
Verlag: Nova Science Publishers Inc, 2010
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: moluna, Greven, Deutschland
Gebunden. Zustand: New. Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. This title describes nearly 150 drugs that are used in routine therapy or are in clinical trials in breast cancer patients, .
Sprache: Englisch
Verlag: Nova Science Publishers Inc Jan 2010, 2010
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Buch. Zustand: Neu. Neuware - Breast cancer is the most frequently diagnosed type of cancer and a second leading cause of cancer death in women after lung cancer. Despite their proven efficacy, classical therapies are, however, unable to cure metastatic breast cancer and are often associated with significant toxicity and side-effects, due to a wide spectrum of action. During the last years, our increasing knowledge of the molecular pathways underlying cancer development has led to the introduction of new drugs, of which most are directed towards very specific targets. Rather than to be used as single agents, these 'modern' compounds could ultimately be combined with classical molecules. Here are described nearly 150 drugs that are currently used in routine therapy or are in clinical trials in breast cancer patients. From the classical tamoxifen, fluorouracil, cyclophosphamide, doxorubicin, epirubin, docetaxel, paclitaxel., to the more recently introduced ixabepilone, lapatinib, vorinostat, everolimus, bevacizumab., they also include capecitabine, gemcitabine, trastuzumab, bevacizumab, fulvestrant, aromatase inhibitors, cancer vaccines, inhibitors of tumour-induced osteolysis, insulin-like growth factor-I receptor inhibitors, poly(ADP-ribose) polymerase (PARP)-1 inhibitors, and many others. This book offers an insight into current developments of breast cancer therapy, when classicism meets modernity.
Sprache: Englisch
Verlag: NOVA SCIENCE PUBLISHERS INC (1/2010), 2009
ISBN 10: 1607415933 ISBN 13: 9781607415930
Anbieter: BOOKIT!, Genève, Schweiz
Zustand: Used: Like New. LIVRE A L?ETAT DE NEUF. EXPEDIE SOUS 3 JOURS OUVRES. NUMERO DE SUIVI COMMUNIQUE AVANT ENVOI, EMBALLAGE RENFORCE. EAN:9781607415930.